Oct 19 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) VRX.TO :
* Reports third quarter 2015 financial results
* Q3 GAAP earnings per share $0.14
* Q3 revenue $2.8 billion versus I/B/E/S view $2.78 billion
* Q3 earnings per share view $2.70 -- Thomson Reuters I/B/E/S
* Qtrly same store sales organic growth of 13%
* Sees same store sales organic growth of greater than 10% for Q4 and FY 2015
* Says Q4 total revenue increased to $3.25 - $3.45 billion from $3.2 - $3.4
billion
* Says 2015 total revenue forecast increased to $11.0 billion - $11.2 billion
from $10.7 billion - $11.1 billion
* Reaffirming our $7.5 billion EBITDA floor for 2016"
* Says Q4 cash EPS increased to $4.00 - $4.20 from $3.98 - $4.18
* Says FY cash EPS increased to $11.67 - $11.87 from $11.50 - $11.80
* Sees 2015 salix revenue of about $1.35 billion
* Qtrly cash earnings per share $2.74
* Source text for Eikon ID:nCNWBLqWGa
* Further company coverage VRX.TO